Pirtobrutinib

匹妥布替尼

Report date: 2026/04/25 20:00:23
NME

Base Information

Drug NamePirtobrutinib
Drug Alias Name吡妥布替尼Jaypirca捷帕力RXC-005LOXO-305 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitorsBTK C481S inhibitors
TargetsTyrosine-protein kinase BTKBTK C481S
Therapy Area/IndicationsThrombocytopeniaPurpura, Thrombocytopenic, IdiopathicRenal Insufficiency +[17] 
Global Approved IndicationsLymphoma, Mantle-Cell
Approved Indications in ChinaLymphoma, Mantle-Cell
Original Approved Country/TerritoryUnited States
Original Approved Date2023/01/27
Country/TerritoryCzechiaBelgiumBulgaria +[39] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesRedx Pharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInnovent Biologics IncEli Lilly Japan KkBend Research Inc +[10] 
Inactive CompaniesNational Heart, Lung, And Blood Institute (Nhlbi)
Active IndicationsThrombocytopeniaPurpura, Thrombocytopenic, IdiopathicRenal Insufficiency +[16] 
Inactive IndicationsMultiple Sclerosis

Other Information

ATC CodeL01EL
Related LinksWikipediaDrugBankKEGG